Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Genomic mapping reveals cisplatin disruption of protein phosphorylation signalling genome-wide.

Metallomics : integrated biometal science·2026
Same author

In Vivo Imaging of a Photoactivatable Platinum Prodrug by Metal-Centered Radiolabeling.

Journal of the American Chemical Society·2026
Same author

A Correlative X‑ray Bioimaging Triad for Metals in Biomedical Research.

Chemical & biomedical imaging·2026
Same author

In Situ Lipid Interactions of an Anticancer Metal Complex.

Inorganic chemistry·2026
Same author

Multichiral Half-Sandwich Ru(II) and Os(II) Anticancer Complexes Containing a Glutathione Synthesis Inhibitor.

Organometallics·2025
Same author

Synthetic methods for key precursors of biologically active dimethylsulfoxide ruthenium complexes.

Dalton transactions (Cambridge, England : 2003)·2025

関連する実験動画

Updated: May 18, 2026

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

トリプトファンのスイッチは,光活性化プラチナ抗がん複合体のためのスイッチです.

Jennifer S Butler1, Julie A Woods, Nicola J Farrer

  • 1Department of Chemistry, University of Warwick, Coventry CV4 7AL, UK.

Journal of the American Chemical Society
|September 21, 2012
PubMed
まとめ

プラチナ (((IV) 複合体トランス,トランス,トランス-[Pt (((N3) 2 (((OH) 2 (((py) 2) 1) は,青い光の照射で強力な癌細胞毒性を示しています. この効果は,アジジル基形成を抑制するl-トリプトファンによって切断されます.

科学分野:

  • 無機化学 無機化学とは
  • フォトケミストリー フォトケミストリー
  • 癌の治療薬について

背景:

  • プラチナ (IV) 複合体は,がん治療のために研究されています.
  • 光活性化されたプラチナ複合体は,強力な細胞毒性を示すことができます.

研究 の 目的:

  • 特定のPt (IV) 複合体の光細胞毒性のメカニズムを調査する.
  • この光細胞毒性の調節におけるl-トリプトファンの役割を調査する.

主な方法:

  • 電子パラマグネティック共振 (EPR) スペクトロスコピー
  • 核磁共振 (NMR) スペクトロスコーピーは,核磁共振 (NMR) スペクトロスコーピーのスペクトロスコーピーを用います.
  • スピントラッピングのテクニック

主要な成果:

  • Pt(IV) 複合体トランス,トランス,トランス-[Pt(N3) 2 ((OH) 2 ((py) 2) (1) は,可視光下での癌細胞に細胞毒性があります.
  • 低用量 (500マイクロM) のl-トリプトファン (l-Trp) は,この光細胞毒性を抑制する.
  • EPRとNMRの研究は,l-Trpが電子ドナーとして作用することでアジジル基形成を抑制することを示しています.

さらに関連する動画

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

関連する実験動画

Last Updated: May 18, 2026

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-(2-[18F]Fluoroethyl)-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
07:20

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

結論:

  • l-トリプトファンは,光化学療法性アジドPt (IV) 薬の活性を制御することができます.
  • ラジカルとPt (II) 光産物を含む二重攻撃メカニズムは,これらのプラチナ複合体の効能に寄与する.